Premier Alternatives

Ancilia Bio

Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)

Developer of virus-resistant live bacterial products designed to modulate the human microbiome. Ancilia Bio is based in New York, NY and was founded in 2019. It was valued at $28 million at its seed round in Apr 2026, the last priced event on record. It has raised $11.1 million across 1 recorded round; the latest was an early-stage round in Apr 2023.

PMV mark · valuation
$28.0M
Oct 2026
Priced at
its seed round
Apr 2026
Total raised
$11.1M
Last round
Early Stage VC
Apr 2023

Ancilia Bio key facts

as of Oct 2026
  • Developer of virus-resistant live bacterial products designed to modulate the human microbiome.
  • Ancilia Bio is valued at approximately $28.0M as of Oct 2026, set at its seed round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $11.1M across 1 recorded rounds; the latest was Early Stage VC in Apr 2023.
  • Notable investors include US National Science Foundation, Metaplanet Holdings, National Institutes of Health, New York Ventures, Spacecadet Ventures — 13 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$28.0M

Valued at $28.0M at its seed round, Apr 2026. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Ancilia Bio with a free account
  • ·The complete investor list: 13 names
  • ·Watch Ancilia Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Ancilia Bio funding rounds

1 rounds
Apr 2023Early Stage VC—▮
Full funding history →

Ancilia Bio valuation

Ancilia Bio was valued at $28 million at its seed round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Ancilia Bio raised?

Ancilia Bio has raised $11.1 million in total; 1 of its rounds is on record. The most recent was an early-stage round in Apr 2023.

Ancilia Bio investors

13 investors are on record for Ancilia Bio, including US National Science Foundation, Metaplanet Holdings, National Institutes of Health and New York Ventures. By type, the record holds 5 venture capital firms. The early-stage round in Apr 2023 drew 2 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Persephone Biosciences ($37.3 million), Solarea Bio ($37 million) and PAhR Therapeutics ($25 million).

About Ancilia Bio

Developer of virus-resistant live bacterial products designed to modulate the human microbiome. The company targets the viral components of the gut microbiome to treat disease and focuses on healthy gut bacteria and their predatory phages to engineer resistant strains, and also develops a new class of live biotherapeutics, enabling medical science professionals to specifically target phages or viruses with a specific affinity for inducing lysis.

Industry
Drug Discovery
Sector
Healthcare
HQ
New York, NY, United States
Founded
2019
Employees
5
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.